Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout
– First participant randomized in the Phase 2 trial for temanogrel in Raynaud’s phenomenon secondary to systemic sclerosis
– Strong liquidity position to support continued pipeline progress
https://finance.yahoo.com/news/arena-reports-third-quarter-financial-200500949.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.